Recursion Pharmaceuticals

Decoding biology demands a bold approach.

Recursion successfully predicted the protein target interactions for approximately 36 billion chemical compounds in the Enamine REAL Space library, taking an important step to bridge the gap between the protein universe and the chemical universe.

Recursion shares press releases and news about its achievements and announcements.

Recursion's careers page describes job opportunities, company culture, and the impact of working there.

The page introduces Recursion's team and discusses its expertise, passion, and vision.

Recursion describes its approach to decoding biology and its mission related to AI drug discovery.

Recursion Pharmaceuticals shares rise 13% as pipeline progress and reduced spending guidance boost sentiment. The company cites REC-4881 progress in familial adenomatous polyposis and Genentech’s clearance of the IND for REC-7735, alongside lower 2026 cash operating expense guidance that extends its expected runway into early 2028.

Aug 2026 · TIKRNews article

An analyst reassessment says Recursion Pharmaceuticals remains behind better-capitalized AI drug discovery peers despite recent Genentech news. It notes Genentech's first neuroscience option exercise and more than $500 million in cumulative partnership milestones, but argues Recursion still lags on cash burn and pipeline stage.

Aug 2026 · Seeking AlphaNews article

Recursion reports a Q2 2026 loss as collaboration revenue falls. The company continues building out its AI-native clinical-stage pipeline.

Aug 2026 · StockTitanNews article

A May 2026 analysis assesses Recursion Pharmaceuticals’ first-quarter results as an execution test for its AI drug-discovery strategy. It centers on a pending FDA update expected in the second half of 2026, which would define the registrational path for REC-4881 in familial adenomatous polyposis.

May 2026 · Merlin TraderNews article